Literature DB >> 8683242

Malignant mesothelioma following treatment for Hodgkin's disease.

L B Weissmann1, J M Corson, A I Neugut, K H Antman.   

Abstract

PURPOSE: Asbestos exposure is the major known risk factor for mesothelioma, but several case reports have suggested a link between radiation therapy and subsequent development of malignant mesothelioma. This report explores a possible association between radiation therapy for Hodgkin's disease and mesothelioma. PATIENTS AND METHODS: Four cases of malignant mesothelioma were observed following Hodgkin's disease at the Mesothelioma Clinic of the Dana-Farber Cancer Institute. A fifth such patient was found after a review of the literature.
RESULTS: In all five cases, the mesothelioma arose in the field of prior radiotherapy. No history of asbestos exposure was elicited by careful questioning or by review of chest radiographs. Examination of lung tissue in one patient showed 250 ferruginous bodies per gram of lung tissue, consistent with no significant prior exposure. The mean interval between radiation treatment for Hodgkin's disease and development of mesothelioma was 15 years, which emphasizes the need for continued follow-up and evaluation of these patients and supports a causal relationship.
CONCLUSION: Mesothelioma may need to be added to the list of second malignancies that arise following radiation therapy for Hodgkin's disease. Further support is given to a causal link between radiation exposure and mesothelioma.

Entities:  

Mesh:

Year:  1996        PMID: 8683242     DOI: 10.1200/JCO.1996.14.7.2098

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  9 in total

Review 1.  Malignant peritoneal mesothelioma: a review.

Authors:  Joseph Kim; Shanel Bhagwandin; Daniel M Labow
Journal:  Ann Transl Med       Date:  2017-06

Review 2.  Advances in malignant peritoneal mesothelioma.

Authors:  Shoubo Cao; Shi Jin; Jingyan Cao; Jing Shen; Jing Hu; Dehai Che; Bo Pan; Jiawen Zhang; Xiaoxi He; Dian Ding; Feifei Gu; Yan Yu
Journal:  Int J Colorectal Dis       Date:  2014-10-21       Impact factor: 2.571

Review 3.  Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.

Authors:  Shoshana J Weiner; Siyamek Neragi-Miandoab
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-12       Impact factor: 4.553

4.  French cohort of the uranium processing workers: mortality pattern after 30-year follow-up.

Authors:  Irina Guseva Canu; Elisabeth Cardis; Camille Metz-Flamant; Sylvaine Caër-Lorho; Bernard Auriol; Pascal Wild; Dominique Laurier; Margot Tirmarche
Journal:  Int Arch Occup Environ Health       Date:  2009-08-23       Impact factor: 3.015

Review 5.  Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Authors:  Noushin Nabavi; Kevin L Bennewith; Andrew Churg; Yuzhuo Wang; Colin C Collins; Luciano Mutti
Journal:  Genes Cancer       Date:  2016-11

6.  Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.

Authors:  Shoshana J Weiner; Siyamek Neragi-Miandoab
Journal:  J Carcinog       Date:  2008-07-28

7.  Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?

Authors:  Andrew J Drain; Kourosh Saeb-Parsy; Amit K Shah; D Rassl; Andrew J Ritchie
Journal:  J Cardiothorac Surg       Date:  2006-11-01       Impact factor: 1.637

8.  Malignant Pleural Mesothelioma in Patients Who Previously Received Radiotherapy for Their First Malignant Tumor.

Authors:  Ikuo Sekine; Yoshiyuki Yamamoto; Toshio Suzuki; Hideo Suzuki
Journal:  Intern Med       Date:  2020-10-14       Impact factor: 1.271

9.  The Association between Malignant Pleural Mesothelioma and Thoracic Radiation Therapy for Hodgkin's Lymphoma: The First Case Report in Japan.

Authors:  Koki Nakashima; Yoshiki Demura; Masahiro Oi; Mio Tabata; Toshihiko Tada; Kohei Shiozaki; Masaya Akai; Tamotsu Ishizuka
Journal:  Intern Med       Date:  2020-10-14       Impact factor: 1.271

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.